{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:08:02Z","timestamp":1793142482944,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T00:00:00Z","timestamp":1743897600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T00:00:00Z","timestamp":1743897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["RX002305"],"award-info":[{"award-number":["RX002305"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Guillain-Barr\u00e9 syndrome (GBS) is a devastating autoimmune disease of the peripheral nervous system (PNS) with limited treatment options. Several studies have shown attenuation of the well-characterized GBS preclinical experimental autoimmune neuritis (EAN) model with systemically administered therapeutic compounds via anti-inflammatory or immunomodulatory mechanisms. Despite this, clinical advancement of these findings is limited by dosing that is not translatable to humans or is associated with off-target and toxic effects. This is due, in part, to the blood-nerve barrier (BNB), which restricts access of the circulation to peripheral nerves. However, during acute neuroinflammation, the normally restrictive BNB exhibits increased vascular permeability and enables immune cell infiltration. This may offer a unique window to access the otherwise restricted peripheral nerve microenvironment for therapeutic delivery. Here, we assessed the degree to which BNB permeability and immune cell infiltration over the course of EAN enables accumulation of circulating nanoparticles. We found that at disease stages defined by distinct clinical scores and pathology (onset, effector phase, and peak of EAN severity), intravenously administered small molecules and nanoparticles ranging from 50 to 150\u00a0nm can permeate into the endoneurium from the endoneurial vasculature in a size- and stage-dependent manner. This permeation occurs uniformly in both sciatic nerves and in proximal and distal regions of the nerves. We propose that this nerve targeting enabled by pathology serves as a platform by which potential therapies for GBS can be reevaluated and investigated preclinically in nanoparticle delivery systems.<\/jats:p>","DOI":"10.1038\/s41598-025-96231-z","type":"journal-article","created":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T09:06:01Z","timestamp":1743930361000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Blood nerve barrier permeability enables nerve targeting of circulating nanoparticles in experimental autoimmune neuritis"],"prefix":"10.1038","volume":"15","author":[{"given":"Chanpreet","family":"Kaur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellaina","family":"Villarreal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maleen H.","family":"Cabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3017-1380","authenticated-orcid":false,"given":"Kelly A.","family":"Langert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,6]]},"reference":[{"key":"96231_CR1","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S0140-6736(16)00339-1","volume":"388","author":"HJ Willison","year":"2016","unstructured":"Willison, H. J., Jacobs, B. C. & van Doorn, P. A. Guillain-Barr\u00e9 syndrome. Lancet 388, 717\u2013727 (2016).","journal-title":"Lancet"},{"key":"96231_CR2","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/j.1529-8027.2009.00215.x","volume":"74","author":"PA Van Doorn","year":"2009","unstructured":"Van Doorn, P. A. What\u2019s new in Guillain-Barre syndrome in 2007\u20132008?. J. Peripher. Nerv. Syst. 74, 72\u201374 (2009).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"96231_CR3","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/brain\/118.4.857","volume":"118","author":"JM Spies","year":"1995","unstructured":"Spies, J. M., Westland, K. W., Bonner, J. G. & Pollard, J. D. Intraneural activated t cells cause focal breakdown of the blood-nerve barrier. Brain 118, 857\u2013868 (1995).","journal-title":"Brain"},{"key":"96231_CR4","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00415-010-5836-5","volume":"258","author":"MO Lu","year":"2011","unstructured":"Lu, M. O. & Zhu, J. The role of cytokines in Guillain-Barr\u00e9 syndrome. J. Neurol. 258, 533\u2013548 (2011).","journal-title":"J. Neurol."},{"key":"96231_CR5","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1177\/0192623319838993","volume":"47","author":"E Tomikawa","year":"2019","unstructured":"Tomikawa, E. et al. Time course of axon and myelin degeneration in peripheral nerves in experimental autoimmune neuritis rats. Toxicol. Pathol. 47, 542\u2013552 (2019).","journal-title":"Toxicol. Pathol."},{"key":"96231_CR6","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s12026-013-8406-y","volume":"56","author":"A Katzav","year":"2013","unstructured":"Katzav, A., Bina, H., Aronovich, R. & Chapman, J. Treatment for experimental autoimmune neuritis with clodronate (Bonefos). Immunol. Res. 56, 334\u2013340 (2013).","journal-title":"Immunol. Res."},{"key":"96231_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-023-02822-w","volume":"20","author":"F Kohle","year":"2023","unstructured":"Kohle, F. et al. Kinesin-5 inhibition improves neural regeneration in experimental autoimmune neuritis. J. Neuroinflamm. 20, 1\u201313 (2023).","journal-title":"J. Neuroinflamm."},{"key":"96231_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0143416","volume":"10","author":"K Pitarokoili","year":"2015","unstructured":"Pitarokoili, K., Ambrosius, B., Meyer, D., Schrewe, L. & Gold, R. Dimethyl fumarate ameliorates Lewis rat experimental autoimmune neuritis and mediates axonal protection. PLoS ONE 10, 1\u201317 (2015).","journal-title":"PLoS ONE"},{"key":"96231_CR9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1093\/brain\/awh328","volume":"128","author":"DA Bechtold","year":"2005","unstructured":"Bechtold, D. A. et al. Axonal protection in experimental autoimmune neuritis by the sodium channel blocking agent flecainide. Brain 128, 18\u201328 (2005).","journal-title":"Brain"},{"key":"96231_CR10","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1007\/s11064-011-0522-2","volume":"36","author":"C Yi","year":"2011","unstructured":"Yi, C. et al. Doxycycline attenuates peripheral inflammation in rat experimental autoimmune neuritis. Neurochem. Res. 36, 1984\u20131990 (2011).","journal-title":"Neurochem. Res."},{"key":"96231_CR11","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1111\/j.1471-4159.2006.04309.x","volume":"100","author":"JP Sarkey","year":"2007","unstructured":"Sarkey, J. P., Richards, M. P. & Stubbs, E. B. Lovastatin attenuates nerve injury in an animal model of Guillain-Barr\u00e9 syndrome. J. Neurochem. 100, 1265\u20131277 (2007).","journal-title":"J. Neurochem."},{"key":"96231_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnins.2018.00887","volume":"12","author":"KA Langert","year":"2018","unstructured":"Langert, K. A. & Brey, E. M. Strategies for targeted delivery to the peripheral nerve. Front. Neurosci. 12, 1\u201310 (2018).","journal-title":"Front. Neurosci."},{"key":"96231_CR13","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1097\/00000542-200607000-00024","volume":"105","author":"SE Abram","year":"2006","unstructured":"Abram, S. E., Yi, J., Fuchs, A. & Hogan, Q. H. Permeability of injured and intact peripheral nerves and dorsal root ganglia. Anesthesiology 105, 146\u2013153 (2006).","journal-title":"Anesthesiology"},{"key":"96231_CR14","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/S0022-510X(99)00328-7","volume":"174","author":"GA Putzu","year":"2000","unstructured":"Putzu, G. A. et al. Immunohistochemical localization of cytokines, C5b\u20139 and ICAM-1 in peripheral nerve of Guillain-Barre Syndrome. J. Neurol. Sci. 174, 16\u201321 (2000).","journal-title":"J. Neurol. Sci."},{"key":"96231_CR15","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00415-016-8204-2","volume":"264","author":"J Berciano","year":"2017","unstructured":"Berciano, J. et al. Proximal nerve lesions in early Guillain-Barr\u00e9 syndrome: implications for pathogenesis and disease classification. J. Neurol. 264, 221\u2013236 (2017).","journal-title":"J. Neurol."},{"key":"96231_CR16","first-page":"180","volume":"229","author":"J Bennett","year":"2010","unstructured":"Bennett, J. et al. Blood-brain barrier disruption and enhanced vascular permeability in the multiple sclerosis model EAE. J. Immunol. 229, 180\u2013191 (2010).","journal-title":"J. Immunol."},{"key":"96231_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep29988","volume":"6","author":"VN Bharadwaj","year":"2016","unstructured":"Bharadwaj, V. N., Lifshitz, J., Adelson, P. D., Kodibagkar, V. D. & Stabenfeldt, S. E. Temporal assessment of nanoparticle accumulation after experimental brain injury: Effect of particle size. Sci. Rep. 6, 1\u201312 (2016).","journal-title":"Sci. Rep."},{"key":"96231_CR18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jconrel.2017.06.013","volume":"261","author":"M Durymanov","year":"2017","unstructured":"Durymanov, M., Kamaletdinova, T., Lehmann, S. E. & Reineke, J. Exploiting passive nanomedicine accumulation at sites of enhanced vascular permeability for non-cancerous applications. J. Control. Release 261, 10\u201322 (2017).","journal-title":"J. Control. Release"},{"key":"96231_CR19","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1021\/mp800051m","volume":"5","author":"F Alexis","year":"2008","unstructured":"Alexis, F., Pridgen, E., Molnar, L. K. & Farokhzad, O. C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 5, 505\u2013515 (2008).","journal-title":"Mol. Pharm."},{"key":"96231_CR20","doi-asserted-by":"publisher","first-page":"935","DOI":"10.2147\/IJN.S121881","volume":"12","author":"P Rafiei","year":"2017","unstructured":"Rafiei, P. & Haddadi, A. Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: Pharmacokinetics and biodistribution profile. Int. J. Nanomed. 12, 935\u2013947 (2017).","journal-title":"Int. J. Nanomed."},{"key":"96231_CR21","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.jconrel.2011.06.001","volume":"153","author":"YH Bae","year":"2011","unstructured":"Bae, Y. H. & Park, K. Targeted drug delivery to tumors: Myths, reality and possibility. J. Control. Release 153, 198\u2013205 (2011).","journal-title":"J. Control. Release"},{"key":"96231_CR22","doi-asserted-by":"publisher","first-page":"571","DOI":"10.3390\/jpm11060571","volume":"11","author":"MA Subhan","year":"2021","unstructured":"Subhan, M. A., Yalamarty, S. S. K., Filipczak, N., Parveen, F. & Torchilin, V. P. Recent advances in tumor targeting via EPR effect for cancer treatment. J. Pers. Med. 11, 571 (2021).","journal-title":"J. Pers. Med."},{"key":"96231_CR23","doi-asserted-by":"publisher","first-page":"3728","DOI":"10.1007\/s00415-020-10034-y","volume":"268","author":"J Berciano","year":"2021","unstructured":"Berciano, J. Axonal degeneration in Guillain-Barr\u00e9 syndrome: a reappraisal. J. Neurol. 268, 3728\u20133743 (2021).","journal-title":"J. Neurol."},{"key":"96231_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.13892","author":"KA Langert","year":"2017","unstructured":"Langert, K. A., Goshu, B. & Stubbs, E. B. Attenuation of experimental autoimmune neuritis with locally administered lovastatin-encapsulating poly(lactic-co-glycolic) acid nanoparticles. J. Neurochem. https:\/\/doi.org\/10.1111\/jnc.13892 (2017).","journal-title":"J. Neurochem."},{"key":"96231_CR25","doi-asserted-by":"publisher","DOI":"10.1177\/1759091415595726","author":"MW Calik","year":"2015","unstructured":"Calik, M. W., Shankarappa, S. A., Langert, K. A. & Stubbs, E. B. Forced exercise preconditioning attenuates experimental autoimmune neuritis by altering Th1 lymphocyte composition and egress. ASN Neuro https:\/\/doi.org\/10.1177\/1759091415595726 (2015).","journal-title":"ASN Neuro"},{"key":"96231_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-017-0864-z","volume":"14","author":"B Ambrosius","year":"2017","unstructured":"Ambrosius, B. et al. Fingolimod attenuates experimental autoimmune neuritis and contributes to Schwann cell-mediated axonal protection. J. Neuroinflamm. 14, 1\u20139 (2017).","journal-title":"J. Neuroinflamm."},{"key":"96231_CR27","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1155\/2018\/7628037","volume":"2018","author":"L Yao","year":"2018","unstructured":"Yao, L., Xue, X., Yu, P., Ni, Y. & Chen, F. Evans blue dye: A revisit of its applications in biomedicine. Contrast Media Mol. Imaging 2018, 18\u201324 (2018).","journal-title":"Contrast Media Mol. Imaging"},{"key":"96231_CR28","doi-asserted-by":"publisher","first-page":"135665","DOI":"10.1016\/j.neulet.2021.135665","volume":"746","author":"J Scalisi","year":"2021","unstructured":"Scalisi, J. et al. Blood-brain barrier permeability towards small and large tracers in a mouse model of osmotic demyelination syndrome. Neurosci. Lett. 746, 135665 (2021).","journal-title":"Neurosci. Lett."},{"key":"96231_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-49028-w","volume":"9","author":"KT Householder","year":"2019","unstructured":"Householder, K. T., Dharmaraj, S., Sandberg, D. I., Wechsler-Reya, R. J. & Sirianni, R. W. Fate of nanoparticles in the central nervous system after intrathecal injection in healthy mice. Sci. Rep. 9, 1\u201311 (2019).","journal-title":"Sci. Rep."},{"key":"96231_CR30","first-page":"332","volume":"48","author":"HC Powell","year":"1983","unstructured":"Powell, H. C., Braheny, S., Myers, R. R., Rodriguez, M. & Lampert, P. Early changes in experimental allergic neuritis. Lab. Investig. 48, 332\u2013338 (1983).","journal-title":"Lab. Investig."},{"key":"96231_CR31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/BF00688630","volume":"68","author":"A Hahn","year":"1985","unstructured":"Hahn, A., Feasby, T. & Gilbert, J. Blood nerve barrier studies in experimental allergic neuritis. Acta Neuropathol. 68, 101\u2013109 (1985).","journal-title":"Acta Neuropathol."},{"key":"96231_CR32","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1093\/jnci\/djj070","volume":"98","author":"MR Dreher","year":"2006","unstructured":"Dreher, M. R. et al. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J. Natl. Cancer Inst. 98, 335\u2013344 (2006).","journal-title":"J. Natl. Cancer Inst."},{"key":"96231_CR33","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1007\/s00018-008-8521-4","volume":"65","author":"Z Zhang","year":"2008","unstructured":"Zhang, Z., Zhang, Z. Y., Fauser, U. & Schluesener, H. J. Valproic acid attenuates inflammation in experimental autoimmune neuritis. Cell. Mol. Life Sci. 65, 4055\u20134065 (2008).","journal-title":"Cell. Mol. Life Sci."},{"key":"96231_CR34","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/jnr.23357","volume":"92","author":"F Han","year":"2014","unstructured":"Han, F. et al. Curcumin ameliorates rat experimental autoimmune neuritis. J. Neurosci. Res. 92, 743\u2013750 (2014).","journal-title":"J. Neurosci. Res."},{"key":"96231_CR35","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1007\/s10753-012-9447-4","volume":"35","author":"H Ramkalawan","year":"2012","unstructured":"Ramkalawan, H. et al. Pioglitazone, PPARgamma agonist, attenuates experimental autoimmune neuritis. Inflammation 35, 1338\u20131347 (2012).","journal-title":"Inflammation"},{"key":"96231_CR36","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/jns5.12032","volume":"18","author":"KA Langert","year":"2013","unstructured":"Langert, K. A., Von Zee, C. L. & Stubbs, E. B. Cdc42 GTPases facilitate TNF-\u03b1-mediated secretion of CCL2 from peripheral nerve microvascular endoneurial endothelial cells. J. Peripher. Nerv. Syst. 18, 199\u2013208 (2013).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"96231_CR37","doi-asserted-by":"publisher","first-page":"e983873","DOI":"10.4161\/sgtp.29260","volume":"5","author":"KA Langert","year":"2014","unstructured":"Langert, K. A., Pervan, C. L. & Stubbs, E. B. Novel role of cdc42 and RalA GTpases in TNF-\u03b1 mediated secretion of CCL2. Small GTPases 5, e983873 (2014).","journal-title":"Small GTPases"},{"key":"96231_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-021-02350-5","volume":"18","author":"F Szepanowski","year":"2021","unstructured":"Szepanowski, F. et al. LPA1 signaling drives Schwann cell dedifferentiation in experimental autoimmune neuritis. J. Neuroinflamm. 18, 1\u201312 (2021).","journal-title":"J. Neuroinflamm."},{"key":"96231_CR39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3389\/fneur.2019.00003","volume":"10","author":"E Shavit-Stein","year":"2019","unstructured":"Shavit-Stein, E. et al. Blocking thrombin significantly ameliorates experimental autoimmune neuritis. Front. Neurol. 10, 3\u201312 (2019).","journal-title":"Front. Neurol."},{"key":"96231_CR40","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.015119","author":"MA Munger","year":"2020","unstructured":"Munger, M. A. et al. Tetrodotoxin-sensitive neuronal-type na+ channels: A novel and druggable target for prevention of atrial fibrillation. J. Am. Heart Assoc. https:\/\/doi.org\/10.1161\/JAHA.119.015119 (2020).","journal-title":"J. Am. Heart Assoc."},{"key":"96231_CR41","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1186\/s12951-024-02892-9","volume":"22","author":"X Cong","year":"2024","unstructured":"Cong, X. et al. Nanocarriers for targeted drug delivery in the vascular system: focus on endothelium. J. Nanobiotechnol. 22, 620 (2024).","journal-title":"J. Nanobiotechnol."},{"key":"96231_CR42","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1248\/bpb.b13-00059","volume":"36","author":"H Hatakeyama","year":"2013","unstructured":"Hatakeyama, H., Akita, H. & Harashima, H. The polyethyleneglycol dilemma: Advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumors. Biol. Pharm. Bull. 36, 892\u2013899 (2013).","journal-title":"Biol. Pharm. Bull."},{"key":"96231_CR43","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/BF00296547","volume":"82","author":"HC Powell","year":"1991","unstructured":"Powell, H. C., Myers, R. R., Mizisin, A. E., Olee, I. & Brostoff, S. W. Response of the axon and barrier endothelium to experimental allergic neuritis induced by autoreactive T cell lines. Acta Neuropathol. Commun. 82, 364\u2013377 (1991).","journal-title":"Acta Neuropathol. Commun."},{"key":"96231_CR44","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s00401-016-1599-0","volume":"132","author":"C Dong","year":"2016","unstructured":"Dong, C., Palladino, S. P., Helton, E. S. & Ubogu, E. E. The pathogenic relevance of \u03b1M-integrin in Guillain-Barr\u00e9 syndrome. Acta Neuropathol. 132, 739\u2013752 (2016).","journal-title":"Acta Neuropathol."},{"key":"96231_CR45","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.devcel.2023.01.002","volume":"58","author":"L Malong","year":"2023","unstructured":"Malong, L. et al. Characterization of the structure and control of the blood-nerve barrier identifies avenues for therapeutic delivery. Dev. Cell 58, 174-191.e8 (2023).","journal-title":"Dev. Cell"},{"key":"96231_CR46","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jddst.2015.06.017","volume":"30","author":"H Al-Obaidi","year":"2015","unstructured":"Al-Obaidi, H. & Florence, A. T. Nanoparticle delivery and particle diffusion in confined and complex environments. J. Drug Deliv. Sci. Technol. 30, 266\u2013277 (2015).","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"96231_CR47","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ejps.2009.02.008","volume":"37","author":"C Chittasupho","year":"2009","unstructured":"Chittasupho, C. et al. ICAM-1 targeting of doxorubicin-loaded PLGA nanoparticles to lung epithelial cells. Eur. J. Pharm. Sci. 37, 141\u2013150 (2009).","journal-title":"Eur. J. Pharm. Sci."},{"key":"96231_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-03422-5","volume":"11","author":"F Yang","year":"2021","unstructured":"Yang, F., Cabe, M. H., Ogle, S. D., Sanchez, V. & Langert, K. A. Optimization of critical parameters for coating of polymeric nanoparticles with plasma membrane vesicles by sonication. Sci. Rep. 11, 1\u201313 (2021).","journal-title":"Sci. Rep."},{"key":"96231_CR49","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1021\/acs.nanolett.8b03439","volume":"19","author":"R Li","year":"2019","unstructured":"Li, R. et al. Route to rheumatoid arthritis by macrophage-derived microvesicle-coated nanoparticles. Nano Lett. 19, 124\u2013134 (2019).","journal-title":"Nano Lett."},{"key":"96231_CR50","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jconrel.2015.10.013","volume":"220","author":"RL Cook","year":"2015","unstructured":"Cook, R. L. et al. A critical evaluation of drug delivery from ligand modified nanoparticles: Confounding small molecule distribution and efficacy in the central nervous system. J. Control. Release 220, 89\u201397 (2015).","journal-title":"J. Control. Release"},{"key":"96231_CR51","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jconrel.2017.02.033","volume":"253","author":"DX Medina","year":"2017","unstructured":"Medina, D. X. et al. Optical barcoding of PLGA for multispectral analysis of nanoparticle fate in vivo. J. Control. Release 253, 172\u2013182 (2017).","journal-title":"J. Control. Release"},{"key":"96231_CR52","first-page":"596","volume-title":"Peripheral Nerve Tissue Engineering and Regeneration","author":"C Prahm","year":"2022","unstructured":"Prahm, C., Heinzel, J. & Kolbenschlag, J. Blood supply and microcirculation of the peripheral nerve. In Peripheral Nerve Tissue Engineering and Regeneration (eds Phillips, J. B. et al.) 596 (Springer Nature, 2022)."},{"key":"96231_CR53","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/0022-510X(92)90070-2","volume":"111","author":"H Kozu","year":"1992","unstructured":"Kozu, H., Tamura, E. & Parry, G. Endoneurial blood supply to peripheral nerves is not uniform. J. Neurol. Sci. 111, 204\u2013208 (1992).","journal-title":"J. Neurol. Sci."},{"key":"96231_CR54","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1124\/jpet.117.245613","volume":"365","author":"H Liu","year":"2018","unstructured":"Liu, H. et al. Drug distribution into peripheral nerve. J. Pharmacol. Exp. Ther. 365, 336\u2013345 (2018).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"96231_CR55","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.3390\/pharmaceutics14112410","volume":"14","author":"E Elahi","year":"2022","unstructured":"Elahi, E. et al. Immune modifying effect of drug free biodegradable nanoparticles on disease course of experimental autoimmune neuritis. Pharmaceutics 14, 2410 (2022).","journal-title":"Pharmaceutics"},{"key":"96231_CR56","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00401-015-1466-4","volume":"130","author":"EE Ubogu","year":"2015","unstructured":"Ubogu, E. E. Inflammatory neuropathies: pathology, molecular markers and targets for specific therapeutic intervention. Acta Neuropathol. 130, 445\u2013468 (2015).","journal-title":"Acta Neuropathol."},{"key":"96231_CR57","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3390\/pharmaceutics14010095","volume":"14","author":"F Yang","year":"2022","unstructured":"Yang, F., Cabe, M., Nowak, H. A. & Langert, K. A. Chitosan\/poly(lactic-co-glycolic)acid nanoparticle formulations with finely-tuned size distributions for enhanced mucoadhesion. Pharmaceutics 14, 95 (2022).","journal-title":"Pharmaceutics"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96231-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96231-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96231-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T23:28:09Z","timestamp":1743982089000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96231-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,6]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["96231"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-96231-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,6]]},"assertion":[{"value":"1 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All experiments were conducted using protocols approved by the Edward Hines, Jr., VA Hospital Institutional Animal Care and Use Committee in accordance with the principles of laboratory animal care.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"11763"}}